Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Systemic inflammation is a key risk factor for hepatocellular carcinoma (HCC) progression and poor outcomes. Inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) may have prognostic value in HCC treated with standard of care atezolizumab plus bevacizumab (Atezo-Bev). We conducted a multicenter, international retrospective cohort study of patients with unresectable HCC treated with Atezo-Bev to assess the association of NLR and PLR with overall survival (OS), progression-free survival (PFS), and objective response rates. Patients with NLR ≥ 5 had a significantly shorter OS (9.38 vs. 16.79 months, p < 0.001) and PFS (4.90 vs. 7.58 months, p = 0.03) compared to patients with NLR < 5. NLR ≥ 5 was an independent prognosticator of worse OS (HR 2.01, 95% CI 1.22−3.56, p = 0.007) but not PFS. PLR ≥ 300 was also significantly associated with decreased OS (9.38 vs. 15.72 months, p = 0.007) and PFS (3.45 vs. 7.11 months, p = 0.04) compared to PLR < 300, but it was not an independent prognosticator of OS or PFS. NLR and PLR were not associated with objective response or disease control rates. NLR ≥ 5 independently prognosticated worse survival outcomes and is worthy of further study and validation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cancers - 14(2022), 23 vom: 26. Nov. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Atezolizumab plus bevacizumab |
|---|
| Anmerkungen: |
Date Revised 08.03.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers14235834 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350095221 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350095221 | ||
| 003 | DE-627 | ||
| 005 | 20231226044159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers14235834 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM350095221 | ||
| 035 | |a (NLM)36497316 | ||
| 035 | |a (PII)5834 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wu, Yue Linda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Systemic inflammation is a key risk factor for hepatocellular carcinoma (HCC) progression and poor outcomes. Inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) may have prognostic value in HCC treated with standard of care atezolizumab plus bevacizumab (Atezo-Bev). We conducted a multicenter, international retrospective cohort study of patients with unresectable HCC treated with Atezo-Bev to assess the association of NLR and PLR with overall survival (OS), progression-free survival (PFS), and objective response rates. Patients with NLR ≥ 5 had a significantly shorter OS (9.38 vs. 16.79 months, p < 0.001) and PFS (4.90 vs. 7.58 months, p = 0.03) compared to patients with NLR < 5. NLR ≥ 5 was an independent prognosticator of worse OS (HR 2.01, 95% CI 1.22−3.56, p = 0.007) but not PFS. PLR ≥ 300 was also significantly associated with decreased OS (9.38 vs. 15.72 months, p = 0.007) and PFS (3.45 vs. 7.11 months, p = 0.04) compared to PLR < 300, but it was not an independent prognosticator of OS or PFS. NLR and PLR were not associated with objective response or disease control rates. NLR ≥ 5 independently prognosticated worse survival outcomes and is worthy of further study and validation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a NLR | |
| 650 | 4 | |a PLR | |
| 650 | 4 | |a atezolizumab plus bevacizumab | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a inflammatory markers | |
| 700 | 1 | |a Fulgenzi, Claudia Angela Maria |e verfasserin |4 aut | |
| 700 | 1 | |a D'Alessio, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Cheon, Jaekyung |e verfasserin |4 aut | |
| 700 | 1 | |a Nishida, Naoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Saeed, Anwaar |e verfasserin |4 aut | |
| 700 | 1 | |a Wietharn, Brooke |e verfasserin |4 aut | |
| 700 | 1 | |a Cammarota, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Pressiani, Tiziana |e verfasserin |4 aut | |
| 700 | 1 | |a Personeni, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Pinter, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Scheiner, Bernhard |e verfasserin |4 aut | |
| 700 | 1 | |a Balcar, Lorenz |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yi-Hsiang |e verfasserin |4 aut | |
| 700 | 1 | |a Phen, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Naqash, Abdul Rafeh |e verfasserin |4 aut | |
| 700 | 1 | |a Vivaldi, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Salani, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Masi, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Bettinger, Dominik |e verfasserin |4 aut | |
| 700 | 1 | |a Vogel, Arndt |e verfasserin |4 aut | |
| 700 | 1 | |a Schönlein, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a von Felden, Johann |e verfasserin |4 aut | |
| 700 | 1 | |a Schulze, Kornelius |e verfasserin |4 aut | |
| 700 | 1 | |a Wege, Henning |e verfasserin |4 aut | |
| 700 | 1 | |a Galle, Peter R |e verfasserin |4 aut | |
| 700 | 1 | |a Kudo, Masatoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Rimassa, Lorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Singal, Amit G |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Rohini |e verfasserin |4 aut | |
| 700 | 1 | |a Cortellini, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Gaillard, Vincent E |e verfasserin |4 aut | |
| 700 | 1 | |a Chon, Hong Jae |e verfasserin |4 aut | |
| 700 | 1 | |a Pinato, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Ang, Celina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 14(2022), 23 vom: 26. Nov. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:23 |g day:26 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers14235834 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 23 |b 26 |c 11 | ||